Plasma Fractionation Industry Outlook 2025-2033

Summary:

• The global plasma fractionation market size reached USD 26.4 Billion in 2024.
• The market is expected to reach USD 26.4 Billion by 2033, exhibiting a growth rate (CAGR) of 4.86% during 2025-2033.
• North America leads the market, accounting for the largest plasma fractionation market share.
• Immunoglobulins accounts for the majority of the market share in the product segment as Immunoglobulins are essential for treating various immune deficiencies and autoimmune diseases.
• The private sector holds the largest share in the plasma fractionation industry.
• Neurology remains a dominant segment in the market, as neurological disorders are increasing, and immunoglobulin therapies have proven effective in treating conditions like guillain-barre syndrome and multiple sclerosis.
• Hospitals and clinics represents the leading end user segment.
• The growing demand for plasma-derived products is the primary driver of the plasma fractionation market.
• Technological advancements and the increasing number of chronic ailments are reshaping the plasma fractionation market.

Request the sample copy of the report: https://www.imarcgroup.com/plasma-fractionation-market/requestsample

Factors Driving the Growth of the Plasma Fractionation Industry:

• Increasing Demand for Plasma-Derived Products:

Plasma-derived products are essential for treating a wide range of medical conditions, including immune deficiencies, bleeding disorders, and liver disease. Immunoglobulins, derived from human plasma, play a crucial role in boosting the immune system and protecting against infections. They are used to treat primary immunodeficiency diseases, autoimmune disorders, and other conditions that impair the immune system. Clotting factors, such as factor VIII and factor IX, are essential for blood clotting and are used to treat hemophilia A and B, respectively. Albumin, a protein found in human plasma, is used to maintain blood volume and pressure, and it is often used in the treatment of shock, burns, and liver disease. As the global population ages and the prevalence of chronic diseases increases, the demand for plasma-derived therapies is expected to continue to grow.

• Rising Incidence of Chronic Diseases:

The increasing incidence of chronic diseases, such as autoimmune disorders, respiratory conditions, and infectious diseases, is driving the demand for plasma-derived therapies. Autoimmune diseases, such as rheumatoid arthritis, lupus, and inflammatory bowel disease, are characterized by an overactive immune system that attacks the body’s own tissues. Plasma-derived therapies, such as intravenous immunoglobulin (IVIG), can help to suppress the immune system and reduce inflammation in these conditions. Respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and asthma, can also benefit from plasma-derived therapies. For example, albumin can be used to treat pulmonary edema, a condition in which fluid accumulates in the lungs. Additionally, plasma-derived therapies may be beneficial for patients with severe respiratory infections, such as pneumonia and influenza.

• Technological Advancements and Innovations:

Technological advancements in plasma fractionation have significantly improved the efficiency and quality of plasma-derived products. Innovations in purification and separation techniques, such as chromatography and ultrafiltration, have enabled the production of purer and more potent products. Additionally, advancements in cryoprecipitation have improved the yield of valuable plasma components, such as cryoprecipitate, which is used to treat hemophilia and other bleeding disorders. These technological advancements have led to increased product availability and reduced production costs, making plasma-derived therapies more accessible to a wider population. As the demand for plasma-derived products continues to grow, the plasma fractionation industry is well-positioned for continued expansion. By leveraging technological advancements, optimizing production processes, and collaborating with healthcare providers, the industry can meet the evolving needs of patients and ensure the availability of life-saving therapies.

Plasma Fractionation Market Report Segmentation:

Breakup By Product:

• Immunoglobulins
• Albumin
• Coagulation factor VIII
• Coagulation factor IX

Immunoglobulins represent the largest segment due to their critical role in treating various immune deficiencies and autoimmune disorders.

Breakup By Sector:

• Private Sector
• Public Sector

Based on the sector, the market is bifurcated into the private and public sectors.

Breakup by Application:

• Neurology
• Immunology
• Hematology
• Other Applications

Neurology is a significant growth driver due to the increasing prevalence of neurological disorders and the efficacy of immunoglobulin therapies in treating conditions like Guillain-Barré syndrome and multiple sclerosis.

Breakup By End User:

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

Hospitals and clinics are the primary end-users of plasma-derived therapies, accounting for the largest share of the market.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds a dominant position in the plasma fractionation market, driven by advanced healthcare infrastructure, high prevalence of blood disorders, and significant investments in biotechnology and pharmaceuticals.

Top Plasma Fractionation Market Leaders:

The plasma fractionation market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• ADMA Biologics
• Bio Products Laboratory Ltd.
• Boccard
• Grifols, S.A.
• Hemarus Therapeutics Limited
• Intas Pharmaceuticals Limited
• LFB S.A.
• Merck Group
• Octapharma AG
• PlasmaGen BioSciences Pvt. Ltd.
• SK Plasma Co. Ltd.
• Virchow Biotech Private Limited

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145